NO931821L - Hepatitis B Vaccine Preparation Containing A Bile Acid Salt - Google Patents

Hepatitis B Vaccine Preparation Containing A Bile Acid Salt

Info

Publication number
NO931821L
NO931821L NO93931821A NO931821A NO931821L NO 931821 L NO931821 L NO 931821L NO 93931821 A NO93931821 A NO 93931821A NO 931821 A NO931821 A NO 931821A NO 931821 L NO931821 L NO 931821L
Authority
NO
Norway
Prior art keywords
hepatitis
methods
hbsag
new
acid salt
Prior art date
Application number
NO93931821A
Other languages
Norwegian (no)
Other versions
NO931821D0 (en
Inventor
Keith E Langley
Grant A Bitter
Raj Kumar Sachdev
John C Fieschko
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1992/007982 external-priority patent/WO1993005811A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO931821D0 publication Critical patent/NO931821D0/en
Publication of NO931821L publication Critical patent/NO931821L/en

Links

Abstract

Høyimmunogent hepatitt B-vaksine-preparat som omfatter HBsAg fremstilt som resultatet av rekombinant gjær-vertscelleekspresjon, og et gallesalt, særlig natriumdeoksycholat, samt fremgangsmåter anvendt til å fremstille vaksinen. Disse fremgangsmåtene omfatter nye gjærdyrkingsbetingelser og nye fremgangsmåter for HBsAg-rensing og tilsetning av hjelpestoffer. Fremgangsmåter hvor disse nye HBsAg-preparater benyttes til å immunisere pattedyr, særlig mennesker, som er mottakelige for hepatitt B-infeksjon.Highly immunogenic hepatitis B vaccine composition comprising HBsAg prepared as a result of recombinant yeast host cell expression, and a bile salt, especially sodium deoxycholate, as well as methods used to prepare the vaccine. These methods include new yeast culture conditions and new methods for HBsAg purification and addition of excipients. Methods using these new HBsAg preparations to immunize mammals, especially humans, susceptible to hepatitis B infection.

NO93931821A 1991-09-18 1993-05-19 Hepatitis B Vaccine Preparation Containing A Bile Acid Salt NO931821L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76267891A 1991-09-18 1991-09-18
PCT/US1992/007982 WO1993005811A1 (en) 1991-09-18 1992-09-18 A hepatitis b vaccine formulation incorporating a bile acid salt

Publications (2)

Publication Number Publication Date
NO931821D0 NO931821D0 (en) 1993-05-19
NO931821L true NO931821L (en) 1993-07-07

Family

ID=26785030

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931821A NO931821L (en) 1991-09-18 1993-05-19 Hepatitis B Vaccine Preparation Containing A Bile Acid Salt

Country Status (1)

Country Link
NO (1) NO931821L (en)

Also Published As

Publication number Publication date
NO931821D0 (en) 1993-05-19

Similar Documents

Publication Publication Date Title
Anderson et al. Enhancement of a secondary antibody response to vesicular stomatitis virus" G" protein by IFN-gamma treatment at primary immunization.
EP1170016A3 (en) Urease-based vaccine against helicobacter infection
EP0339667A2 (en) Hepatitis A,B,-combined adjuvanted vaccine
LU91610I2 (en) Protein D and its pharmaceutically acceptable derivatives (SYNFLORIX - Conjugated polysaccharide pneumococcal vaccine (adsorbed)
NO167359C (en) PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS.
DK0528859T3 (en) Oral vaccine which includes antigen attached to the surface of red blood cells
AU7589587A (en) Low dosage of interferon to enhance vaccine efficiency
NO983474L (en) Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines
NO950483L (en) Hepatitis A vaccine
ATE101200T1 (en) VACCINES AGAINST HUMAN RESPIRATORY VIRUSES.
DK53285A (en) (-) - TRANS-4 (4-FLUORPHENYL) -3- (4-METHOXYPHENOXY) METHYLPIPERIDINE, PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
DK0666751T3 (en) Hepatitis A virus mutants, strain HM-175, for use as hepatitis A vaccines
DK0506778T3 (en) Substituted 4-phenyl-4-piperidinecarboxamides with both local anesthetic and analgesic action as well as methods for their preparation
SE9903031D0 (en) Peptide mixture and vaccine against a chronic viral infection
ES379641A1 (en) Ethylethyleneimine as an inactivation agent
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
ES8504459A1 (en) Transfer factor for use in treating viral infections.
CO4980849A1 (en) PHARMACEUTICAL COMPOSITIONS -2-HIDROXIMETIL-1,3-OXATIOLAN-5-IL) - (1H) -PIRIMIDIN-2-ONA (LA MIVUDINA), AND ITS USE IN MEDICAL THERAPY
NO931821L (en) Hepatitis B Vaccine Preparation Containing A Bile Acid Salt
CA2254082A1 (en) Metastatic colorectal cancer vaccine
DE69015314D1 (en) USE OF ADENYL CYCLASE AS A VACCINE AGAINST BORDETELLA.
DE69114519T2 (en) APPLICATION OF IL-4 TO INCREASE THE IMMUNE RESPONSE TO IMMUNOGENES IN VACCINE SUBSTANCES.
YU45292A (en) DIFFERENT HEPATITIS B VIRUS SURFACE PROTEINS FORMING PARTICLES
AU1227700A (en) Method for the production of purified invasin protein and use thereof
Davidson et al. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals